Sandeep Kulkarni, Chief Executive Officer - Tourmaline Bio (TRML)
Tourmaline Bio (Nasdaq: TRML) is a late-stage clinical biotechnology company dedicated to developing transformative medicines for patients suffering from life-altering immune and inflammatory diseases. Led by Dr. Sandeep Kulkarni, co-founder and CEO, and supported by a team of well-accomplished entrepreneurs, physicians, and industry experts, the company establishes new standards of care in areas with high unmet medical needs.Dr. Kulkarni’s professional journey began with Boston Consulting Group, where he advised leading biopharma companies on strategic and operational projects. He then served as a biotech investor at QVT Financial before assuming the position of CEO at Immunovent. During his tenure at Immunovent, Dr. Kulkarni played a role in advancing the organization from an internally incubated project into a fully integrated biotech company, culminating in a successful public offering.
Concurrent with his position at Immunovent, Dr. Kulkarni served as the Vice President of Special Projects at Roivant Sciences. He subsequently transitioned to managing director at KVP Capital, investing in public and private companies while leading the formation activities. Dr. Kulkarni currently serves on the board of directors at Zura Bio and has an executive role at Tourmaline Bio.
His extensive experience as an entrepreneur, life science investor, management consultant, and medical doctor spans nearly two decades of professional expertise within the healthcare industry. Drawing on this expertise, Dr. Kulkarni established Tourmaline Bio, leading the company’s ongoing clinical trials to evaluate its proprietary investigational study drug, pacibekitug—also referred to as TOUR006—a long-acting, fully human monoclonal antibody.
“Our extensive clinical experience with pacibekitug allows us to advance directly into late-stage, pivotal programs, facilitating rapid delivery of the drug candidate to patients,” says Dr. Kulkarni.
He spearheaded the development of this drug candidate to explore its potential in treating thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). While TED could lead to eye inflammation, discomfort, disfigurement, and potential vision loss, ASCVD encompasses life-threatening conditions like heart attack and acute limb ischemia, which continue to pose significant health risks despite the available treatments. These conditions are further aggravated by elevated levels of Interleukin-6 (IL-6), a key cytokine involved in the pathogenesis of several autoimmune and inflammatory diseases in the human body.
To navigate these complexities and provide enhanced patient treatment outcomes, Dr. Kulkarni guides the team at Tourmaline Bio to develop pacibekitug with best-in-class potential and distinct properties. These properties include a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. The drug candidate has been studied in hundreds of autoimmune patients, demonstrating its ability to inhibit the IL-6 signaling pathway with relatively low drug exposure. It also has the potential to be infrequently administered by a low-volume, subcutaneous injection.
He spearheaded the development of this drug candidate to explore its potential in treating thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). While TED could lead to eye inflammation, discomfort, disfigurement, and potential vision loss, ASCVD encompasses life-threatening conditions like heart attack and acute limb ischemia, which continue to pose significant health risks despite the available treatments. These conditions are further aggravated by elevated levels of Interleukin-6 (IL-6), a key cytokine involved in the pathogenesis of several autoimmune and inflammatory diseases in the human body.
To navigate these complexities and provide enhanced patient treatment outcomes, Dr. Kulkarni guides the team at Tourmaline Bio to develop pacibekitug with best-in-class potential and distinct properties. These properties include a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. The drug candidate has been studied in hundreds of autoimmune patients, demonstrating its ability to inhibit the IL-6 signaling pathway with relatively low drug exposure. It also has the potential to be infrequently administered by a low-volume, subcutaneous injection.
"Our extensive clinical experience with pacibekitug allows us to advance directly into late-stage, pivotal programs, facilitating rapid delivery of the drug candidate to patients. "
The company’s strategy to maximize the therapeutic potential of pacibekitug involves leveraging published observations and insights from competitive clinical trials of IL-6 pathway inhibitors and targeting indications where these inhibitors have been underexplored. With his exceptional academic qualifications, Dr. Kulkarni is uniquely positioned to lead the company in identifying and pursuing these high-potential opportunities to drive Pacibekitug’s differentiated profile forward and capitalize on external de-risking events.
This educational background, which includes a bachelor’s degree in Economics from Harvard University and a medical degree from the University of California, contributes to Dr. Kulkarni’s deep proficiency in business and healthcare. His vision for better healthcare aligns with the company’s dedication to understanding and proactively addressing patient needs. By leveraging the collective strengths of the entire team, Tourmaline Bio challenges the status quo and overcomes obstacles, striving to deliver transformative healthcare outcomes and enhance patient lives worldwide.